Cargando…
IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
BACKGROUND: Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of this st...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581959/ https://www.ncbi.nlm.nih.gov/pubmed/34763711 http://dx.doi.org/10.1186/s13063-021-05719-2 |
_version_ | 1784596886965977088 |
---|---|
author | Vergis, N. Patel, V. Bogdanowicz, K. Czyzewska-Khan, J. Fiorentino, F. Day, E. Cross, M. Foster, N. Lord, E. Goldin, R. Forrest, E. Thursz, M. |
author_facet | Vergis, N. Patel, V. Bogdanowicz, K. Czyzewska-Khan, J. Fiorentino, F. Day, E. Cross, M. Foster, N. Lord, E. Goldin, R. Forrest, E. Thursz, M. |
author_sort | Vergis, N. |
collection | PubMed |
description | BACKGROUND: Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of this study is to explore the potential benefits of the IL-1β antibody, canakinumab, in the treatment of AH. METHODS: This is a multicentre, double-blind, randomised placebo-controlled trial. Participants will be diagnosed with AH using clinical criteria. Liver biopsy will then confirm that all histological features of AH are present. Up to 58 participants will be recruited into two groups from 15 centres in the UK. Patients will receive an infusion of Canakinumab or matched placebo by random 1:1 allocation. The primary outcome is the difference between groups in the proportion of patients demonstrating histological improvement and will compare histological appearances at baseline with appearances at 28 days to assign a category of “improved” or “not improved”. Patients with evidence of ongoing disease activity will receive a second infusion of canakinumab or placebo. Participants will be followed up for 90 days. Secondary outcomes include mortality and change in MELD score at 90 days. DISCUSSION: This phase II study will explore the benefits of the IL-1β antibody, canakinumab, in the treatment of AH to provide proof of concept that inhibition of IL-1β signalling may improve histology and survival for patients with AH. TRIAL REGISTRATION: EudraCT 2017-003724-79. Prospectively registered on 13 April 2018. |
format | Online Article Text |
id | pubmed-8581959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85819592021-11-12 IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis Vergis, N. Patel, V. Bogdanowicz, K. Czyzewska-Khan, J. Fiorentino, F. Day, E. Cross, M. Foster, N. Lord, E. Goldin, R. Forrest, E. Thursz, M. Trials Study Protocol BACKGROUND: Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of this study is to explore the potential benefits of the IL-1β antibody, canakinumab, in the treatment of AH. METHODS: This is a multicentre, double-blind, randomised placebo-controlled trial. Participants will be diagnosed with AH using clinical criteria. Liver biopsy will then confirm that all histological features of AH are present. Up to 58 participants will be recruited into two groups from 15 centres in the UK. Patients will receive an infusion of Canakinumab or matched placebo by random 1:1 allocation. The primary outcome is the difference between groups in the proportion of patients demonstrating histological improvement and will compare histological appearances at baseline with appearances at 28 days to assign a category of “improved” or “not improved”. Patients with evidence of ongoing disease activity will receive a second infusion of canakinumab or placebo. Participants will be followed up for 90 days. Secondary outcomes include mortality and change in MELD score at 90 days. DISCUSSION: This phase II study will explore the benefits of the IL-1β antibody, canakinumab, in the treatment of AH to provide proof of concept that inhibition of IL-1β signalling may improve histology and survival for patients with AH. TRIAL REGISTRATION: EudraCT 2017-003724-79. Prospectively registered on 13 April 2018. BioMed Central 2021-11-11 /pmc/articles/PMC8581959/ /pubmed/34763711 http://dx.doi.org/10.1186/s13063-021-05719-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Vergis, N. Patel, V. Bogdanowicz, K. Czyzewska-Khan, J. Fiorentino, F. Day, E. Cross, M. Foster, N. Lord, E. Goldin, R. Forrest, E. Thursz, M. IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
title | IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
title_full | IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
title_fullStr | IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
title_full_unstemmed | IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
title_short | IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
title_sort | il-1 signal inhibition in alcoholic hepatitis (isaiah): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581959/ https://www.ncbi.nlm.nih.gov/pubmed/34763711 http://dx.doi.org/10.1186/s13063-021-05719-2 |
work_keys_str_mv | AT vergisn il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT patelv il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT bogdanowiczk il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT czyzewskakhanj il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT fiorentinof il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT daye il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT crossm il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT fostern il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT lorde il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT goldinr il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT forreste il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis AT thurszm il1signalinhibitioninalcoholichepatitisisaiahastudyprotocolforamulticentrerandomisedplacebocontrolledtrialtoexplorethepotentialbenefitsofcanakinumabinthetreatmentofalcoholichepatitis |